Дијагностичка вредност растворљивог ST2, MIC-1 и NLR код плућне хипертензије повезане са хроничном опструктивном болешћу плућа

Раствориви ST2, MIC-1 и NLR код ХОБП

  • Wei Chen Одељење пулмологије, Површна болница Универзитета за кинеску медицину у Нанђингу
  • Guoling Lyu Одељење кардиологије, болница Шангај Хангдао
  • Qinghua Shi Одељење за магацин, болница Ђинлинг, Медицински факултет Универзитета у Нанђингу
  • Xubin Li Болница Ренмин Универзитета у Вухану
  • Xinyu Li Renmin Hospital of Wuhan University
  • Yurong Huang Одељење за респираторну и интензивну медицину, Болница Корпуса за производњу и изградњу Синђијанга
DOI: https://doi.org/10.5937/jomb0-62049
Ključne reči: Раствориви туморогени фактор-2, Хронична опструктивна плућна болест, Пулмонална артеријска хипертензија, Дијагностичка ефикасност, Makrofagski inhibitorijski citokin-1

Sažetak


[Objective] To explore the diagnostic efficacy of serum soluble tumorigenic factor-2 (Soluble ST2), Macrophage Inhibitory Cytokine-1 (MIC-1), and  neutrophil/lymphocyte ratio (NLR) for the poor prognosis of pulmonary hypertension (PH) associated with chronic obstructive pulmonary disease (COPD).

[Methods] The COPD mixed with PH group consisted of 242 patients who received a diagnosis of COPD combined with PH at our hospital between January 2023 and December 2024. Patients with COPD and PH were further separated into two groups: those with a fair prognosis (186 patients) and those with a bad prognosis (56 patients).  90 healthy people who had physical examinations were chosen as the healthy control group, and another 150 patients with uncomplicated COPD within the same time period were chosen as the COPD group. Multivariate analysis of the effects of serum Soluble ST2 and MIC-1 levels and the NLR on the prognosis of COPD combined with PH in each group, the relationships between serum Soluble ST2 and MIC-1 levels and the NLR and the severity of COPD combined with PH, and the diagnostic value of COPD combined with PH for poor prognosis.

[Results] The COPD combined with PH group's serum Soluble ST2, MIC-1, and NLR levels were noticeably higher. Compared with the healthy control group, the COPD group presented significantly greater differences (P<0.05), which increased with increasing severity of PH. The group with a good prognosis had a considerably higher level of left ventricular ejection fraction (LVEF) than the group with a poor prognosis, whereas the levels of serum Soluble ST2, MIC-1 and NLR in the poor prognosis group were significantly greater than those in the good prognosis group, and the differences were statistically significant (P<0.05). There were no statistically significant differences in age, sex, disease duration, hypertension status, diabetes status, triglyceride, cholesterol, high-density lipoprotein or low-density lipoprotein levels (P>0.05).

[Conclusion] The levels of serum Soluble ST2 and MIC-1 and the NLR are indicators reflecting the severity of COPD combined with PH. The combined detection of these three indicators is helpful for improving the diagnostic efficacy for the poor prognosis of patients with COPD combined with PH.

Reference

1.Zhou D, Liu C, Wang L, Li J, Zhao Y, Deng Z, Hou C, Fu Y, Jiang Q, Lai N, Zhang R, Feng W, Gao C, Li X, Jiang M, Fu X, Chen J, Hong W, Xu L, He W, Liu J, Yang Y, Lu W, Zhong N, Cao Y, Wang J, Chen Y. Prediction of clinical risk assessment and survival in chronic obstructive pulmonary disease with pulmonary hypertension. Clin Transl Med. 2024 Jun;14(6):e1702. doi: 10.1002/ctm2.1702. PMID: 38861300; PMCID: PMC11166097.
2.Atchley WT, Kakkera TK. Pulmonary hypertension in chronic obstructive pulmonary disease: current understanding, knowledge gaps and future directions. Curr Opin Pulm Med. 2024 Mar 1;30(2):150-155. doi: 10.1097/MCP.0000000000001041. Epub 2023 Dec 13. PMID: 38088383.
3.Chazova IE, Lazareva NV, Oshchepkova EV. Arterial hypertension and chronic obstructive pulmonary disease: clinical characteristics and treatment efficasy (according to the national register of arterial hypertension). Ter Arkh. 2019 Mar 29;91(3):4-10. doi: 10.26442/00403660.2019.03.000110. PMID: 31094451.
4.Atchley WT, Kakkera TK. Pulmonary hypertension in chronic obstructive pulmonary disease: current understanding, knowledge gaps and future directions. Curr Opin Pulm Med. 2024 Mar 1;30(2):150-155. doi: 10.1097/MCP.0000000000001041. Epub 2023 Dec 13. PMID: 38088383.
5.Adir Y, Harari S. Pulmonary hypertension associated with chronic obstructive lung disease and idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2014 Sep;20(5):414-20. doi: 10.1097/MCP.0000000000000084. PMID: 25046428.
6.Higenbottam T. Pulmonary hypertension and chronic obstructive pulmonary disease: a case for treatment. Proc Am Thorac Soc. 2005;2(1):12-9. doi: 10.1513/pats.200411-053SF. PMID: 16113463.
7.Wang L, Wang F, Tuo Y, Wan H, Luo F. Clinical characteristics and predictors of pulmonary hypertension in chronic obstructive pulmonary disease at different altitudes. BMC Pulm Med. 2023 Apr 18;23(1):127. doi: 10.1186/s12890-023-02405-8. Erratum in: BMC Pulm Med. 2023 Jun 5;23(1):192. doi: 10.1186/s12890-023-02493-6. PMID: 37072815; PMCID: PMC10111800.
8.Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(1):20-2. doi: 10.1513/pats.200407-037MS. PMID: 16113464.
9.Yang D, Wang L, Jiang P, Kang R, Xie Y. Correlation between hs-CRP, IL-6, IL-10, ET-1, and Chronic Obstructive Pulmonary Disease Combined with Pulmonary Hypertension. J Healthc Eng. 2022 Feb 10;2022:3247807. doi: 10.1155/2022/3247807. PMID: 35186226; PMCID: PMC8853794.
10.Tian Z, Cen L. Interaction of Biochemical Processes between Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension (PAH), and Coronavirus Disease 2019 (COVID-19). Pol J Microbiol. 2023 Jun 14;72(2):143-154. doi: 10.33073/pjm-2023-015. PMID: 37216361; PMCID: PMC10266291.
11.Barberà JA, Blanco I. Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management. Drugs. 2009 Jun 18;69(9):1153-71. doi: 10.2165/00003495-200969090-00002. PMID: 19537834.
12.Almagro P, Boixeda R, Diez-Manglano J, Gómez-Antúnez M, López-García F, Recio J. Insights into Chronic Obstructive Pulmonary Disease as Critical Risk Factor for Cardiovascular Disease. Int J Chron Obstruct Pulmon Dis. 2020 Apr 14;15:755-764. doi: 10.2147/COPD.S238214. PMID: 32341642; PMCID: PMC7166051.
13.Wu L, Li X, Yan J. Commentary: Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in cholangiocarcinoma. Transl Oncol. 2024 Jul;45:101995. doi: 10.1016/j.tranon.2024.101995. Epub 2024 May 9. PMID: 38789241.
14.Yan J, Duan Y, Cheng M. Clinical Diagnostic Value of Serum GABA, NE, ET-1, and VEGF in Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension. Int J Chron Obstruct Pulmon Dis. 2023 Aug 19;18:1803-1813. doi: 10.2147/COPD.S418478. PMID: 37621655; PMCID: PMC10445639.
15.Andersen CU, Mellemkjær S, Nielsen-Kudsk JE, Bendstrup E, Hilberg O, Simonsen U. Pulmonary hypertension in chronic obstructive and interstitial lung diseases. Int J Cardiol. 2013 Oct 3;168(3):1795-804. doi: 10.1016/j.ijcard.2013.06.033. Epub 2013 Jul 11. PMID: 23849967.
16.Wu L, Chen X, Zeng Q, Lai Z, Fan Z, Ruan X, Li X, Yan J. NR5A2 gene affects the overall survival of LUAD patients by regulating the activity of CSCs through SNP pathway by OCLR algorithm and immune score. Heliyon. 2024 Mar 28;10(7):e28282. doi: 10.1016/j.heliyon.2024.e28282. PMID: 38601554; PMCID: PMC11004709.
17.Fujii H, Taniguchi Y, Yoneda S, Miwa K, Matsuoka Y, Yanaka K, Tsuboi Y, Emoto N, Hirata K. Efficacy and Safety of Balloon Pulmonary Angioplasty for Patients With Chronic Thromboembolic Pulmonary Hypertension and Comorbid Chronic Obstructive Pulmonary Disease. J Am Heart Assoc. 2023 Feb 7;12(3):e026466. doi: 10.1161/JAHA.122.026466. Epub 2023 Feb 3. PMID: 36734336; PMCID: PMC9973616.
18.Tayutina TV, Klimenko NU, Lysenko AV, Kazaryan TM, Modebaddze EV. [Combination of chronic obstructive pulmonary disease and arterial hypertension in elderly individuals: clinical and hemodynamic features and quality of life.]. Adv Gerontol. 2023;36(1):126-133. Russian. PMID: 37192364.
19.Wu L, Li X, Qian X, Wang S, Liu J, Yan J. Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity. Vaccines (Basel). 2024 Feb 12;12(2):186. doi: 10.3390/vaccines12020186. PMID: 38400169; PMCID: PMC10891594.
20.Pan D, Liu R, Ren S, Li C, Chang Q. Prediction of Pulmonary Arterial Hypertension in Chronic Obstructive Lung Disease from Three-Dimensional Vectorcardiographic Parameters. Ann Noninvasive Electrocardiol. 2016 May;21(3):280-6. doi: 10.1111/anec.12305. Epub 2015 Sep 28. PMID: 26414072; PMCID: PMC6931868.
21.Gonzalez-Garcia M, Aguirre-Franco CE, Vargas-Ramirez L, Barrero M, Torres-Duque CA. Effect of pulmonary hypertension on exercise capacity and gas exchange in patients with chronic obstructive pulmonary disease living at high altitude. Chron Respir Dis. 2022 Jan-Dec;19:14799731221104095. doi: 10.1177/14799731221104095. PMID: 35603864; PMCID: PMC9127868.
22.Weitzenblum E, Chaouat A, Kessler R. Pulmonary hypertension in chronic obstructive pulmonary disease. Pneumonol Alergol Pol. 2013;81(4):390-8. PMID: 23744170.
23.Rangelov BA, Young AL, Jacob J, Cahn AP, Lee S, Wilson FJ, Hawkes DJ, Hurst JR. Thoracic Imaging at Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review. Int J Chron Obstruct Pulmon Dis. 2020 Jul 22;15:1751-1787. doi: 10.2147/COPD.S250746. PMID: 32801677; PMCID: PMC7385406.
24.Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. International Journal of Bioprinting. 2024, 10(1), 1256. doi: 10.36922/ijb.1256.
25.Li R, Song M, Wang R, Su N, E L. Can CT-Based Arterial and Venous Morphological Markers of Chronic Obstructive Pulmonary Disease Explain Pulmonary Vascular Remodeling? Acad Radiol. 2024 Jan;31(1):22-34. doi: 10.1016/j.acra.2023.04.026. Epub 2023 May 27. PMID: 37248100.
26.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
27.Rodionova VV, Boiko OO. AGGRAVATING EFFECT OF ARTERIAL HYPERTENSION ON THE COURSE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN PATIENTS WITH COMORBID PATHOLOGY. Wiad Lek. 2021;74(4):973-976. PMID: 34156014.
28.Rabahi MF, Pereira SA, Silva Júnior JL, de Rezende AP, Castro da Costa A, de Sousa Corrêa K, Conde MB. Prevalence of chronic obstructive pulmonary disease among patients with systemic arterial hypertension without respiratory symptoms. Int J Chron Obstruct Pulmon Dis. 2015 Jul 31;10:1525-9. doi: 10.2147/COPD.S85588. PMID: 26257517; PMCID: PMC4527375.
29.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
30.Takei N, Suzuki M, Tanabe N, Oguma A, Shimizu K, Kimura H, Makita H, Sato S, Hirai T, Yokota I, Konno S, Nishimura M. Combined assessment of pulmonary arterial enlargement and coronary calcification predicts the prognosis of patients with chronic obstructive pulmonary disease. Respir Med. 2021 Aug-Sep;185:106520. doi: 10.1016/j.rmed.2021.106520. Epub 2021 Jun 23. PMID: 34182266.
31.Portillo K, Torralba Y, Blanco I, Burgos F, Rodriguez-Roisin R, Rios J, Roca J, Barberà JA. Pulmonary hemodynamic profile in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015 Jul 14;10:1313-20. doi: 10.2147/COPD.S78180. Erratum in: Int J Chron Obstruct Pulmon Dis. 2015 Nov 04;10:2377. doi: 10.2147/COPD.S96102. PMID: 26203238; PMCID: PMC4507485.
32.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
33.Marushchak M, Maksiv K, Krynytska I. The specific features of free radical oxidation in patients with chronic obstructive pulmonary disease and arterial hypertension. Pol Merkur Lekarski. 2019 Sep 25;47(279):95-98. PMID: 31557137.
34.Marushchak M, Maksiv K, Krynytska I, Stechyshyn I. Glutathione antioxidant system of lymphocytes in the blood of patients in a setting of concomitant chronic obstructive pulmonary disease and arterial hypertension. Pol Merkur Lekarski. 2019 Nov 29;47(281):177-182. PMID: 31812971.
35.Jyothula S, Safdar Z. Update on pulmonary hypertension complicating chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2009;4:351-63. doi: 10.2147/copd.s5102. Epub 2009 Sep 24. PMID: 19802350; PMCID: PMC2754087.
36.Zuo ZT, Ma Y, Sun Y, Bai CQ, Zhou HY, Chen BH. Role of TLR4/NF-κB Signaling Pathway in Pulmonary Arterial Hypertension in Patients with Chronic Obstructive Pulmonary Disease. J Coll Physicians Surg Pak. 2020 Jun;30(6):568-573. doi: 10.29271/jcpsp.2020.06.568. PMID: 32703338.
37.Marushchak M, Maksiv K, Krynytska I, Dutchak O, Behosh N. The Severity of Oxidative Stress in Comorbid Chronic Obstructive Pulmonary Disease (COPD) and Hypertension: Does it Depend On ACE and AGT Gene Polymorphisms? J Med Life. 2019 Oct-Dec;12(4):426-434. doi: 10.25122/jml-2019-0108. PMID: 32025262; PMCID: PMC6993293.
38.Aksenova TA, Gorbunov VV, Tsarenok SY. Pulse wave velocity and other indicators of arterial stiffness in hypertension comorbidity and chronic obstructive pulmonary disease. Ter Arkh. 2018 Apr 19;90(3):10-15. doi: 10.26442/terarkh201890310-15. PMID: 30701849.
Objavljeno
2026/03/23
Broj časopisa
Ahead of print
Rubrika
Original paper

Sva prava zadržana (c) 2026 Wei Chen, Guoling Lyu, Qinghua Shi, Xubin Li, Xinyu Li, Yurong Huang

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.